This is a single arm phase II clinical trial, which aims to evaluate the effectiveness of intercalated combination of doublet chemotherapy of paclitaxel plus carboplatin and erlotinib on patients with advanced stage non-small-cell lung cancer with low abundant activating EGFR mutation.
Name: Intercalated combination of chemotherapy and erlotinib
Description: From start of anti-cancer therapy untill progression or deathMeasure: Progression free survival defined by imagery methods Time: 8 weeks
Description: From start of anti-cancer therapy till progression of deathMeasure: Toxicities related to anti-cancer therapy Time: 8 weeks
Single Group Assignment
There is one SNP
Low abundant activating EGFR mutation: EGFR exon 19 deletion or exon 21 L858R, which are positive by real-time PCR methods and negative by standard sequencing methods. --- L858R ---